Glary Pharmaceuticals Private Limited
Wholesale trading of pharmaceutical and chemical products for various applications.
2007 | Lucknow, Uttar Pradesh (India) | Active
Glary Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 17 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.90 M
- Revenue Growth 2.95%
- Profit Growth -15.69%
- Ebitda -86.72%
- Net Worth 15.15%
- Total Assets 4.27%
About Glary Pharmaceuticals
Glary Pharmaceuticals Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 May 2007 and has a history of 17 years and nine months. Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.90 M.
Asha Singh and Nilam Singh serve as directors at the Company.
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233UP2007PTC033337
- Company No.
033337
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 May 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Pharma
Who are the key members and board of directors at Glary Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Asha Singh  | Director | 20-Apr-2019 | Current |
| Nilam Singh | Director | 08-Jun-2015 | Current |
Financial Performance of Glary Pharmaceuticals.
Glary Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 2.95% increase. The company also saw a substantial fall in profitability, with a 15.69% decrease in profit. The company's net worth Soared by an impressive increase of 15.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glary Pharmaceuticals?
In 2018, Glary Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
Open Charges
₹0.90 M
Satisfied Charges
₹0
Charges Breakdown by Lending Institutions
- Allahabad Bank : 0.09 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Jun 2014 | Allahabad Bank | ₹0.90 M | Open |
How Many Employees Work at Glary Pharmaceuticals?
Unlock and access historical data on people associated with Glary Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glary Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glary Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
